JERSEY CITY, N.J., June 14, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the appointment of Nkechi Azie, MD, MBA, FIDSA, as Vice President of Clinical Development, effective June 10, 2019. Dr. Azie will lead clinical development activities and strengthen medical affairs...
Category: News
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019
Summit Therapeutics plc(‘Summit’, the ‘Company’ or the ‘Group’) Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended 30 April 2019 Oxford, UK, and Cambridge, MA, US, 12 June 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) today reports its financial results and provides an update on its operational progress for the first...
Notice of First Quarter Results
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Therapeutics Provides Notice of Financial Results for the First Quarter Ended 30 April 2019 Oxford, UK, and Cambridge, MA, US, 5 June 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism antibiotic innovation, will announce its financial results for the first quarter...
SCYNEXIS to Present Data at ASM Microbe 2019 Demonstrating the Broad Potential Utility of Ibrexafungerp for the Treatment and Prevention of Multiple Severe Fungal Infections
JERSEY CITY, N.J., June 5, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that a total of nine presentations revealing data which further demonstrates the potential of ibrexafungerp as a treatment for invasive fungal infections, will be presented at the American Society for Microbiology...
Nabriva Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, Ireland, June 04, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that it has granted non-statutory stock options to purchase an aggregate of 37,500 ordinary shares of Nabriva Therapeutics as inducements to two newly-hired employees. The...
SCYNEXIS Reports Completion of Chronic Nonclinical Toxicology Studies Supporting Long-Term Administration of Ibrexafungerp
JERSEY CITY, N.J., May 30, 2019 /PRNewswire/ — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the company has completed the nonclinical toxicology evaluations that are required by regulatory authorities, including the U.S. Food and Drug Administration (FDA), to support long-term administration in human clinical...
X-Biotix Therapeutics, Inc. Strengthens Leadership Team with Key Appointments
X-Biotix Therapeutics, Inc. Strengthens Leadership Team with Key Appointments Announces Additions of Dr. David N. Cook to Board of Directors and Dr. Boudewijn DeJonge to Leadership Team WALTHAM, Mass. May 30, 2019 – X-Biotix Therapeutics, Inc. (X-Biotix), a biotechnology company focused on the discovery and development of multiple novel antibiotic first-in-class compounds targeting multidrug-resistant (MDR)...
Motif Bio plc AGM Statement
NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) — Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Company’s AGM held earlier today the Company provided the following review of key aspects of its business and growth strategy. Iclaprim for treating ABSSSI (acute bacterial skin and...
Nabriva Therapeutics to Present at the Jefferies 2019 Healthcare Conference
DUBLIN, Ireland and KING OF PRUSSIA, Pa., May 22, 2019 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Officer, will provide a company overview and business update at the Jefferies 2019 Healthcare Conference...
Motif Bio to Evaluate Orphan Disease Opportunity for Iclaprim in Ophthalmology
NEW YORK, May 22, 2019 (GLOBE NEWSWIRE) — Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed an agreement with Otto-von-Guericke University Magdeburg to conduct a study evaluating iclaprim in an in vitro model of ocular toxoplasmosis. The research will focus on toxoplasma...